Theresa Heggie, Director at BIOCRYST PHARMACEUTICALS INC (BCRX), sold 49,933 shares at $10.11 ($505K) on 2026-03-20, disclosed to the SEC on 2026-03-24.
Seasonal sale ($505k) by Director — this insider has traded BCRX in March in at least three consecutive prior years. Pattern-driven, low signal.
Negative factors outweigh the positive ones.
| Filing → |
| BCRX | BUY | 2019-11-18 | $7K | — | Filing → |